Recommended

New webinar: Overcoming critical challenges in AI-driven drug discovery
Watch on demand: Rapid cell-based profiling of multi-target anti-obesity drugs Watch here!
Download now: Unlock the power of stem cell therapy and discover the potential for new therapies for primary open-angle glaucoma
Brand new Beyond the Lab report on antibodies… Download NOW!
webinar

Leveraging innovative strategies for speedy cell line development

Watch this roundtable of industry experts as they discuss technologies, best practices and strategies for delivering robust, stable, high-yielding cell lines to accelerate and streamline the drug discovery process.

About this virtual panel

Cell line development (CLD) involves the derivation of clones from single cells. Thousands of these clones are then screened to identify those that are stable, produce high yields of bioproducts and exhibit the desired critical quality attributes (CQAs). Any misstep during this critically important phase can jeopardise or delay the path to product commercialisation.

Gain insights into how the incorporation of innovative tools and technologies such as automated systems and high-throughput analytical screening tools can eliminate bottlenecks in clone selection, fast-track development timelines and reduce the cost per experiment.

Watch this roundtable of industry experts as they discuss technologies, best practices and strategies for delivering robust, stable, high-yielding cell lines to accelerate and streamline the drug discovery process.

Learning outcomes of this virtual panel

  • Understand the importance of identifying high performing cell lines early in the development process
  • Explore analytical tools and techniques to optimise cell line development and selection workflows
  • Discover a toolbox for accelerating your path to commercialisation while minimising risk.

Our speakers

Dr Raja SrinivasRaja Srinivas, PhD, Co-Founder, Asimov

In 2017, Raja Srinivas cofounded Asimov, a biotech start-up that brings together synthetic biology with machine learning and automation to advance the design and manufacture of biologics and gene therapies.

Raja received his undergraduate degree at Johns Hopkins University and his doctorate at MIT.

Dr Susan SharfsteinSusan Sharfstein, PhD, Professor of Nanobioscience in the College of Nanoscale Science and Engineering, SUNY Polytechnic Institute

Dr Susan Sharfstein is a Professor of Nanobioscience at SUNY Polytechnic Institute in Albany, New York. She received her BS in chemical engineering with honours from Caltech in 1987 and her PhD in chemical engineering from UC Berkeley in 1993. She received an NIH fellowship to pursue postdoctoral studies, initially at UC Berkeley and subsequently at UCLA Medical School. Sharfstein joined the bioengineering faculty at the University of Toledo in 1996. In 2001, she joined the Department of Chemical and Biological Engineering at Rensselaer Polytechnic Institute and in 2010, Sharfstein joined the faculty at SUNY Polytechnic Institute. She is the author of over 70 papers and book chapters in the fields of biotechnology and bioprocessing.

Saurabh SenSaurabh Sen, PhD, Associate Director, Cell Line Development, Genomic Medicine Unit CMC, Sanofi

Saurabh Sen, PhD, is a research scientist with domain expertise in gene therapy, antibody therapeutics, proteomics, GPCRs and CNS disorders (Parkinson’s disease). In his current position at Sanofi, he is actively engaged in cell line development (CLD), delivering top class producer cell lines (PCLs) for gene therapy and stable cell lines for biologics (mAbs and complex modalities). Previously at Boehringer Ingelheim, Saurabh led end-to-end antibody discovery projects (from early discovery to final humanised/optimised leads for pre-clinical development), developing new therapeutics for unmet medical needs; as well as being the SME for antibody expression (transient and pools).